Pipeline

Cue Biopharma is working at the cutting edge of the immunotherapy revolution, with the potential to offer patients significant therapeutic advantages while minimizing or eliminating unwanted side effects. Our goal is to develop and bring to market biologics that can overcome the challenges faced by prevailing immunotherapeutics, via direct engagement with and modulation of disease-associated T cells in a patient’s body.

CUE pipeline

Immuno-Oncology

CUE-100 Series - MHC Class I / IL-2

DrugDiscoveryOptimizationIND-EnablingPhase IDevelopment Partner
CUE-101 (HPV-E7 / IL-2)
 
CUE-102 (WT1 / IL-2)
 
CUE-103 (Undisclosed / IL-2)

Chronic Infectious Disease

CUE-200 Series - MHC Class I / CD80 and 4-1BBL

DrugDiscoveryOptimizationIND-EnablingPhase IDevelopment Partner
CUE-201

Autoimmune Disease

CUE-300 Series - MHC Class I & II / Undisclosed

DrugDiscoveryOptimizationIND-EnablingPhase IDevelopment Partner
CUE-301